MCKESSON CORP MCK Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0000927653-25-000036
cik 927653
name MCKESSON CORP
sic 5122
countryba US
stprba TX
cityba IRVING
zipba 75039
bas1 6555 STATE HIGHWAY 161
bas2
baph 972-446-4800
countryma US
stprma TX
cityma IRVING
zipma 75039
mas1 6555 STATE HIGHWAY 161
mas2
countryinc US
stprinc DE
ein 943207296
former MCKESSON HBOC INC
changed 19990115
afs 1-LAF
wksi 1
fye 0331
form 10-K
period 20250331
fy 2024
fp FY
filed 20250509
accepted 2025-05-08 17:34:00.0
prevrpt 0
detail 1
instance mck-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0000927653-25-000036 20250331 Accrued Liabilities Current 4825000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Additional Paid In Capital 8048000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Additional Paid In Capital 8373000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 226000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 226000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Assets 75140000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Cash And Cash Equivalents At Carrying Value 4583000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240630 Common Stock Dividends Per Share Declared 0.6200 USD 1 us-gaap/2024
0000927653-25-000036 20250331 Common Stock Dividends Per Share Declared 2.7500 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Common Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0000927653-25-000036 20230331 Common Stock Shares Outstanding 277000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20250331 Common Stock Value 3000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Cost Of Goods And Services Sold 345728000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Earnings Per Share Diluted 25.7200 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 6000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Finite Lived Intangible Assets Net 388000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Service Agreements;
0000927653-25-000036 20250331 Finite Lived Intangible Assets Net 100000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Trademarks And Trade Names;
0000927653-25-000036 20230331 Gain Loss On Sale Of Other Assets 211000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Gain Loss Related To Litigation Settlement -114000000.0000 USD 4 us-gaap/2024 Loss Contingencies By Nature Of Contingency= National Prescription Opiate Litigation;
0000927653-25-000036 20240331 Goodwill 10132000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Goodwill 2536000000.0000 USD 0 us-gaap/2024 Business Segments= Medical Surgical Solutions Segment;
0000927653-25-000036 20250331 Goodwill 2027000000.0000 USD 0 us-gaap/2024 Business Segments= Prescription Technology Solutions;
0000927653-25-000036 20250331 Gross Profit 13323000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 4630000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Loss From Continuing Operations Per Basic Share 25.8600 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Continuing Operations Per Diluted Share 25.0500 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Discontinued Operations Net Of Tax -3000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Accounts Payable 4587000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Accounts Payable 8301000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Accrued Taxes Payable 363000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Deferred Income Taxes 110000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Litigation Reserve -1088000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Increase Decrease In Operating Lease Liability -404000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Other Operating Capital Net 281000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Receivables 1082000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Interest Expense Nonoperating 252000000.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000927653-25-000036 20250331 Interest Expense Nonoperating 265000000.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000927653-25-000036 20250331 Inventory Net 23001000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Long Term Debt And Capital Lease Obligations 4463000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Long Term Debt And Capital Lease Obligations Current 1191000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 150000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Net Cash Provided By Used In Financing Activities -3965000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Cash Provided By Used In Operating Activities 5159000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Nonoperating Income Expense 132000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Assets Noncurrent 3972000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax -63000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax -8000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax -9000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax 24000000.0000 USD 4 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax -7000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -63000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent;
0000927653-25-000036 20240331 Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long Term Debt 647000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long Term Debt 0.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20240331 Payments For Repurchase Of Common Stock 3025000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Preferred Stock Shares Authorized 100000000.0000 shares 0 us-gaap/2024
0000927653-25-000036 20250331 Proceeds From Issuance Of Long Term Debt 498000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 101000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Profit Loss 3481000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Property Plant And Equipment Net 2316000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Receivables Net Current 25643000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230228 Repayments Of Long Term Debt 360000000.0000 USD 0 us-gaap/2024 Debt Instrument= A285 Notes Due March152023; Longterm Debt Type= Loans Payable;
0000927653-25-000036 20230331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000927653-25-000036 20240331 Revenue From Contract With Customer Excluding Assessed Tax 308951000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Revenue From Contract With Customer Excluding Assessed Tax 278739000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20240331 Selling General And Administrative Expense 8657000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1504000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1534000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 10000000.0000 USD 0 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 480000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -8000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -905000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -16000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -881000000.0000 USD 0 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 3000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 372000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -24119000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -932000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20250331 Stockholders Equity Other 0.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20250331 Stock Repurchased During Period Value 3172000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20220331 Treasury Stock Common Shares 130000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20230331 Treasury Stock Common Shares 141000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Weighted Average Number Of Shares Outstanding Basic 133200000.0000 shares 4 us-gaap/2024
0000927653-25-000036 20240331 Depreciation 253000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Earnings Per Share Diluted 25.0300 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 25000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Gain Loss Related To Litigation Settlement 8000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Gain Loss Related To Litigation Settlement -57000000.0000 USD 4 us-gaap/2024 Business Segments= Corporate Segment And U. S. Pharmaceutical Segment; Loss Contingencies By Nature Of Contingency= National Prescription Opiate Litigation;
0000927653-25-000036 20230331 Goodwill 1439000000.0000 USD 0 us-gaap/2024 Business Segments= International Segment;
0000927653-25-000036 20240331 Goodwill 1449000000.0000 USD 0 us-gaap/2024 Business Segments= International Segment;
0000927653-25-000036 20240331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share 0.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share -0.0200 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Income Taxes Paid Net 901000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Long Term Debt And Capital Lease Obligations Current 50000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 152000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 3560000000.0000 USD 4 0000927653-25-000036 Equity Components= Retained Earnings;
0000927653-25-000036 20250331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 186000000.0000 USD 4 0000927653-25-000036 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20240331 Operating Lease Right Of Use Asset 1729000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Other Asset Impairment Charges 98000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax -7000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax -74000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax 62000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax 673000000.0000 USD 4 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax -51000000.0000 USD 4 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -24000000.0000 USD 4 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Portion Attributable To Parent;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 629000000.0000 USD 4 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax 8000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Liabilities Noncurrent 2659000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Payments Of Dividends Common Stock 345000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Payments To Acquire Property Plant And Equipment 390000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Payments To Acquire Property Plant And Equipment 537000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Proceeds From Divestiture Of Businesses And Interests In Affiliates 47000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Proceeds From Issuance Of Long Term Debt 997000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Proceeds From Short Term Debt 19964000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240831 Repayments Of Long Term Debt 500000000.0000 USD 0 us-gaap/2024 Debt Instrument= A525 Notes Due February152026; Longterm Debt Type= Loans Payable;
0000927653-25-000036 20230331 Repayments Of Short Term Debt 8450000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Restructuring Costs And Asset Impairment Charges 209000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Revenue From Contract With Customer Excluding Assessed Tax 11110000000.0000 USD 4 us-gaap/2024 Business Segments= Medical Surgical Solutions Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20240331 Revenue From Contract With Customer Excluding Assessed Tax 14130000000.0000 USD 4 us-gaap/2024 Business Segments= International Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20230331 Selling General And Administrative Expense 7776000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Selling General And Administrative Expense 1100000000.0000 USD 4 us-gaap/2024 Product Or Service= Shipping And Handling;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 7275000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1490000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 12295000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 47000000.0000 USD 0 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -27439000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20230331 Stockholders Equity Other 7000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Stock Issued During Period Shares Employee Stock Plans Net Of Forfeitures 2000000.0000 shares 4 0000927653-25-000036 Equity Components= Common Stock;
0000927653-25-000036 20250331 Stock Issued During Period Shares Employee Stock Plans Net Of Forfeitures 1000000.0000 shares 4 0000927653-25-000036 Equity Components= Common Stock;
0000927653-25-000036 20240331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 17000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 101000000.0000 USD 4 0000927653-25-000036 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Treasury Stock Common Value 27439000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Accounts Payable Current 55330000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -932000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Assets 601000000.0000 USD 0 us-gaap/2024 Consolidated Entities= Variable Interest Entity Primary Beneficiary;
0000927653-25-000036 20240331 Common Stock Shares Issued 278000000.0000 shares 0 us-gaap/2024
0000927653-25-000036 20230331 Comprehensive Income Net Of Tax 4189000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Comprehensive Income Net Of Tax 3026000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Depreciation 242000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Earnings Per Share Basic 22.5400 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -16000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Finite Lived Intangible Assets Net 825000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Customer Relationships;
0000927653-25-000036 20230331 Formation Of Business 22000000.0000 USD 4 0000927653-25-000036 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20221031 Goodwill 113000000.0000 USD 0 us-gaap/2024 Business Acquisition= S C R I Oncology L L C; Business Segments= U S Pharmaceutical Segment;
0000927653-25-000036 20230331 Goodwill 2005000000.0000 USD 0 us-gaap/2024 Business Segments= Prescription Technology Solutions;
0000927653-25-000036 20240331 Income Loss From Continuing Operations Per Basic Share 22.5400 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -0.0200 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share 0.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Tax Expense Benefit 905000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Accounts Payable 3788000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Accrued Taxes Payable 331000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Deferred Income Taxes 20000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Inventories 1259000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Inventories 1294000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Inventories 2270000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Inventory L I F O Reserve Period Charge 82000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Inventory L I F O Reserve Period Charge 82000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20240331 Litigation Reserve Noncurrent 6113000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 178000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Net Cash Provided By Used In Financing Activities -4368000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 158000000.0000 USD 4 0000927653-25-000036 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20240331 Operating Expenses 8919000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Operating Lease Liability Noncurrent 1466000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax 674000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax 39000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 24000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax -30000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Liabilities Noncurrent 2610000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Other Noncash Income Expense -253000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Payments For Proceeds From Other Investing Activities 194000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Payments For Proceeds From Other Investing Activities 29000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Payments To Acquire Software 256000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Prepaid Expense And Other Assets Current 626000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Proceeds From Payments For Other Financing Activities -175000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Proceeds From Short Term Debt 8450000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20221130 Repayments Of Long Term Debt 400000000.0000 USD 0 us-gaap/2024 Debt Instrument= A270 Notes Due December152022; Longterm Debt Type= Loans Payable;
0000927653-25-000036 20250331 Repayments Of Long Term Debt 519000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Revenue From Contract With Customer Excluding Assessed Tax 20598000000.0000 USD 4 us-gaap/2024 Business Segments= International Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20230331 Revenue From Contract With Customer Excluding Assessed Tax 4387000000.0000 USD 4 us-gaap/2024 Business Segments= Prescription Technology Solutions Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20230331 Revenue From Contract With Customer Excluding Assessed Tax 240616000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20240331 Selling General And Administrative Expense 1100000000.0000 USD 4 us-gaap/2024 Product Or Service= Shipping And Handling;
0000927653-25-000036 20250331 Selling General And Administrative Expense 8507000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1534000000.0000 USD 0 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 9030000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -12000000.0000 USD 0 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 14000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -989000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -932000000.0000 USD 0 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 17921000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20240331 Stockholders Equity Other -1000000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20250331 Stockholders Equity Other 2000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Stock Issued During Period Shares Employee Stock Plans Net Of Forfeitures 1000000.0000 shares 4 0000927653-25-000036 Equity Components= Common Stock;
0000927653-25-000036 20230331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 163000000.0000 USD 4 0000927653-25-000036 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20230331 Adjustment For Amortization 360000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Adjustment For Amortization 382000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Adjustments To Additional Paid In Capital Exercise Of Put Right -5000000.0000 USD 4 0000927653-25-000036 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 161000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 182000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Cash And Cash Equivalents At Carrying Value 4678000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 744000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Cash Cash Equivalents Restricted Cash Classified Within Assets Held For Sale Period Increase Decrease 0.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20230331 Common Stock Dividends Per Share Declared 2.0900 USD 4 us-gaap/2024
0000927653-25-000036 20240930 Common Stock Dividends Per Share Declared 0.7100 USD 1 us-gaap/2024
0000927653-25-000036 20250331 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Common Stock Shares Authorized 800000000.0000 shares 0 us-gaap/2024
0000927653-25-000036 20240331 Common Stock Shares Outstanding 278000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20230331 Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 206000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 4395000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 3430000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Derecognition Of Noncontrolling Interests 382000000.0000 USD 4 0000927653-25-000036 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Dividends Common Stock Cash 296000000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20250331 Earnings Per Share Basic 25.8600 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Finite Lived Intangible Assets Net 1129000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Customer Relationships;
0000927653-25-000036 20240331 Finite Lived Intangible Assets Net 8000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Other Intangible Assets;
0000927653-25-000036 20240331 Finite Lived Intangible Assets Net 450000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Service Agreements;
0000927653-25-000036 20250331 Finite Lived Intangible Assets Net 147000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Technology Based Intangible Assets;
0000927653-25-000036 20230331 Formation Of Business 247000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20240331 Gain Loss On Sale Of Other Assets 17000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Gain Loss On Sale Of Other Assets -485000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Goodwill 2024000000.0000 USD 0 us-gaap/2024 Business Segments= Prescription Technology Solutions;
0000927653-25-000036 20240331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share 0.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Income Tax Expense Benefit 629000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Accrued Taxes Payable -136000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Interest Paid Net 234000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Interest Paid Net 273000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Liabilities Current 52357000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Minority Interest 380000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 150000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20240331 Net Income Loss Attributable To Noncontrolling Interest 158000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 162000000.0000 USD 4 0000927653-25-000036 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20240331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 3002000000.0000 USD 4 0000927653-25-000036 Equity Components= Retained Earnings;
0000927653-25-000036 20250331 Nonoperating Income Expense 202000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Operating Lease Expense 249000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Operating Lease Liability Current 295000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Payments To Acquire Businesses Net Of Cash Acquired 867000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000927653-25-000036 20240331 Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 116000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Property Plant And Equipment Net 2502000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Provision For Doubtful Accounts -206000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment;
0000927653-25-000036 20230630 Repayments Of Long Term Debt 268000000.0000 USD 0 us-gaap/2024 Debt Instrument= A380 Notes Due March152024; Longterm Debt Type= Loans Payable;
0000927653-25-000036 20240331 Repayments Of Long Term Debt 288000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Repayments Of Short Term Debt 15086000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 1100000000.0000 USD 4 us-gaap/2024 Business Segments= U. S. Pharmaceuticaland Specialty Solutions; Related Party Transactions By Related Party= Investee;
0000927653-25-000036 20230331 Selling General And Administrative Expense 1200000000.0000 USD 4 us-gaap/2024 Product Or Service= Shipping And Handling;
0000927653-25-000036 20250331 Stockholders Equity -2074000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1792000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -847000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 7747000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -905000000.0000 USD 0 us-gaap/2024 Equity Components= Aoci Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -856000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Other 1000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20250331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures -47000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Stock Repurchased During Period Shares 6000000.0000 shares 4 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Stock Repurchased During Period Value 3023000000.0000 USD 4 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Accrued Liabilities Current 4915000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Assets Current 55398000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20220331 Common Stock Shares Outstanding 275000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20250331 Common Stock Shares Outstanding 279000000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20250331 Comprehensive Income Net Of Tax 3244000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 158000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Derecognition Of Noncontrolling Interests 382000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20240331 Dividends Common Stock Cash 320000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Dividends Common Stock Cash 352000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Dividends Common Stock Cash 352000000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20240331 Finite Lived Intangible Assets Net 159000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Technology Based Intangible Assets;
0000927653-25-000036 20250331 Finite Lived Intangible Assets Net 1464000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Formation Of Business 225000000.0000 USD 4 0000927653-25-000036 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20240331 Gain Loss Related To Litigation Settlement -147000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Gain Loss Related To Litigation Settlement -149000000.0000 USD 4 us-gaap/2024 Loss Contingencies By Nature Of Contingency= National Prescription Opiate Litigation;
0000927653-25-000036 20230331 Goodwill 4050000000.0000 USD 0 us-gaap/2024 Business Segments= U S Pharmaceutical Segment;
0000927653-25-000036 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 4359000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 3160000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Loss From Continuing Operations Per Diluted Share 25.7200 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Taxes Paid Net 1124000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Deferred Income Taxes 603000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Increase Decrease In Operating Lease Liability -338000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Operating Lease Liability -339000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Interest Expense Nonoperating 248000000.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000927653-25-000036 20240331 Interest Expense Nonoperating 252000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Liabilities Current 61604000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 152000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Net Cash Provided By Used In Operating Activities 6085000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Net Income Loss 3295000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Net Income Loss Attributable To Noncontrolling Interest 186000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20250331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 3481000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Operating Income Loss 4422000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Operating Lease Liability Current 258000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Operating Lease Right Of Use Asset 1782000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax 673000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 673000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -51000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax -62000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Noncash Income Expense -233000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Payments To Acquire Property Plant And Equipment 431000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Proceeds From Divestiture Of Businesses And Interests In Affiliates 1077000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Proceeds From Issuance Of Long Term Debt 991000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Proceeds From Short Term Debt 15086000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Provision For Doubtful Accounts 819000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Receivables Net Current 21622000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Receivables Net Current 313000000.0000 USD 0 us-gaap/2024 Business Segments= U. S. Pharmaceuticaland Specialty Solutions; Related Party Transactions By Related Party= Investee;
0000927653-25-000036 20230331 Restricted Cash Current 1000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Restructuring Costs And Asset Impairment Charges 115000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Restructuring Costs And Asset Impairment Charges 286000000.0000 USD 4 us-gaap/2024 Income Statement Location= Restructuring Impairment And Related Charges Net;
0000927653-25-000036 20230331 Revenue From Contract With Customer Excluding Assessed Tax 276711000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Revenue From Contract With Customer Excluding Assessed Tax 4769000000.0000 USD 4 us-gaap/2024 Business Segments= Prescription Technology Solutions Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20240331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 11386000000.0000 USD 4 us-gaap/2024 Business Segments= Medical Surgical Solutions Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 27000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 3000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 367000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -20997000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 14978000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20240331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 116000000.0000 USD 4 0000927653-25-000036 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20230331 Stock Repurchased During Period Shares 11000000.0000 shares 4 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20230331 Stock Repurchased During Period Value 3792000000.0000 USD 4 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20250331 Stock Repurchased During Period Value 3172000000.0000 USD 4 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Weighted Average Number Of Diluted Shares Outstanding 134100000.0000 shares 4 us-gaap/2024
0000927653-25-000036 20250331 Adjustment For Amortization 394000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Assets 67443000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -94000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Cash Cash Equivalents Restricted Cash Classified Within Assets Held For Sale Period Increase Decrease 470000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0000927653-25-000036 20240331 Common Stock Value 3000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 3184000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Cost Of Goods And Services Sold 296123000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Dividends Common Stock Cash 320000000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20230331 Earnings Per Share Basic 25.2300 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Finite Lived Intangible Assets Net 2110000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Gain Loss Related To Litigation Settlement -75000000.0000 USD 4 us-gaap/2024 Business Segments= Corporate; Loss Contingencies By Nature Of Contingency= National Prescription Opiate Litigation;
0000927653-25-000036 20240331 Gain Loss Related To Litigation Settlement -74000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Loss Contingencies By Nature Of Contingency= National Prescription Opiate Litigation;
0000927653-25-000036 20221031 Goodwill 463000000.0000 USD 0 us-gaap/2024 Business Acquisition= Rx Savings Solutions L L C; Business Segments= Rx Ts Segment;
0000927653-25-000036 20230331 Goodwill 0.0000 USD 0 us-gaap/2024 Business Segments= Corporate;
0000927653-25-000036 20240331 Goodwill 0.0000 USD 0 us-gaap/2024 Business Segments= Corporate;
0000927653-25-000036 20250331 Goodwill 10022000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Goodwill 1327000000.0000 USD 0 us-gaap/2024 Business Segments= International Segment;
0000927653-25-000036 20250331 Goodwill 4132000000.0000 USD 0 us-gaap/2024 Business Segments= U S Pharmaceutical Segment;
0000927653-25-000036 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 3789000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 3725000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Loss From Discontinued Operations Net Of Tax 0.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Litigation Reserve -401000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Interest Expense Nonoperating 265000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Inventory L I F O Reserve Period Charge 1000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Inventory Net 21139000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Minority Interest 372000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Net Cash Provided By Used In Financing Activities -3342000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Cash Provided By Used In Investing Activities -542000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Net Cash Provided By Used In Investing Activities -733000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Net Cash Provided By Used In Operating Activities 4314000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Income Loss Attributable To Noncontrolling Interest 162000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Net Income Loss Attributable To Noncontrolling Interest 162000000.0000 USD 4 us-gaap/2024 Ownership= Vantageand Clarus One Sourcing Services L L C;
0000927653-25-000036 20240331 Net Income Loss Attributable To Noncontrolling Interest 158000000.0000 USD 4 us-gaap/2024 Ownership= Vantageand Clarus One Sourcing Services L L C;
0000927653-25-000036 20250331 Net Income Loss Attributable To Noncontrolling Interest 186000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 3295000000.0000 USD 4 0000927653-25-000036 Equity Components= Retained Earnings;
0000927653-25-000036 20230331 Nonoperating Income Expense 497000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Operating Income Loss 4381000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Asset Impairment Charges 43000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax -7000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax 698000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax -24000000.0000 USD 4 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax -133000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 629000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 657000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -51000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20240331 Payments For Proceeds From Other Investing Activities 160000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long Term Debt 0.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20230331 Payments Of Dividends Common Stock 292000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Preferred Stock Shares Authorized 100000000.0000 shares 0 us-gaap/2024
0000927653-25-000036 20250331 Prepaid Expense And Other Assets Current 1063000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 163000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Proceeds From Payments For Other Financing Activities -324000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Restricted Cash Current 2000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Restructuring Costs And Asset Impairment Charges 58000000.0000 USD 4 us-gaap/2024 Income Statement Location= Cost Of Sales;
0000927653-25-000036 20250331 Retained Earnings Accumulated Deficit 17921000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 14721000000.0000 USD 4 us-gaap/2024 Business Segments= International Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 5216000000.0000 USD 4 us-gaap/2024 Business Segments= Prescription Technology Solutions Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -67000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -36000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 8048000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1694000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 8373000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 3000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20230331 Stockholders Equity Other 7000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 161000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Assets 610000000.0000 USD 0 us-gaap/2024 Consolidated Entities= Variable Interest Entity Primary Beneficiary;
0000927653-25-000036 20240331 Assets Current 47970000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 4585000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Cost Of Goods And Services Sold 264353000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Depreciation 248000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Accumulated Other Comprehensive Income Loss Net Of Tax -881000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 182000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 186000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Dividends Common Stock Cash 296000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Earnings Per Share Diluted 22.3900 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Goodwill 9947000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Goodwill 2453000000.0000 USD 0 us-gaap/2024 Business Segments= Medical Surgical Solutions Segment;
0000927653-25-000036 20240331 Goodwill 4123000000.0000 USD 0 us-gaap/2024 Business Segments= U S Pharmaceutical Segment;
0000927653-25-000036 20230331 Gross Profit 12358000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Taxes Paid Net 562000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Tax Expense Benefit 878000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Litigation Reserve -395000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20230331 Increase Decrease In Other Operating Capital Net -56000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Other Operating Capital Net -37000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Interest Expense Nonoperating 248000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Interest Paid Net 224000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Inventory L I F O Reserve Period Charge 1000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20240331 Liabilities And Stockholders Equity 67443000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Liabilities And Stockholders Equity 75140000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Long Term Debt And Capital Lease Obligations 5579000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Net Income Loss 3002000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Income Loss Attributable To Noncontrolling Interest 162000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Net Income Loss Attributable To Noncontrolling Interest 158000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20250331 Net Income Loss Attributable To Noncontrolling Interest 186000000.0000 USD 4 us-gaap/2024 Ownership= Vantageand Clarus One Sourcing Services L L C;
0000927653-25-000036 20240331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 3160000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Operating Expenses 8901000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Operating Lease Expense 245000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Operating Lease Liability Noncurrent 1478000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Other Asset Impairment Charges 72000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax -51000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 59000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Unamortized Gain Loss;
0000927653-25-000036 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 44000000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Payments For Repurchase Of Common Stock 3638000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Payments To Acquire Businesses Net Of Cash Acquired 272000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Preferred Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000927653-25-000036 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000927653-25-000036 20250331 Proceeds From Divestiture Of Businesses And Interests In Affiliates 179000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Profit Loss 3160000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Provision For Doubtful Accounts 725000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment;
0000927653-25-000036 20230331 Repayments Of Long Term Debt 1274000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Restructuring Costs And Asset Impairment Charges 286000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Revenue From Contract With Customer Excluding Assessed Tax 11313000000.0000 USD 4 us-gaap/2024 Business Segments= Medical Surgical Solutions Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 359051000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Stockholders Equity -1971000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -14000000.0000 USD 0 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1599000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 3000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -881000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 380000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Other 1000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20240331 Stockholders Equity Other -3000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Stockholders Equity Other -3000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures -148000000.0000 USD 4 0000927653-25-000036 Equity Components= Treasury Stock Common;
0000927653-25-000036 20230331 Stock Repurchased During Period Value 3665000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Weighted Average Number Of Diluted Shares Outstanding 142200000.0000 shares 4 us-gaap/2024
0000927653-25-000036 20250331 Weighted Average Number Of Shares Outstanding Basic 127400000.0000 shares 4 us-gaap/2024
0000927653-25-000036 20240331 Accounts Payable Current 47097000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Stockholders Equity Other 2000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20250331 Stockholders Equity Other 0.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000927653-25-000036 20230331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 1000000.0000 USD 4 0000927653-25-000036 Equity Components= Common Stock;
0000927653-25-000036 20220228 Stock Repurchased During Period Shares 5100000.0000 shares 0 us-gaap/2024 Share Repurchase Program= Accelerated Share Repurchase;
0000927653-25-000036 20240331 Stock Repurchased During Period Shares 7000000.0000 shares 4 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20230331 Stock Repurchased During Period Value -127000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000927653-25-000036 20240331 Treasury Stock Common Shares 148000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20250331 Treasury Stock Common Shares 154000000.0000 shares 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Treasury Stock Common Value 24119000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Adjustments To Additional Paid In Capital Exercise Of Put Right -5000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20250331 Cash And Cash Equivalents At Carrying Value 5691000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20220331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 3935000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 4679000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5956000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 1371000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Cash Cash Equivalents Restricted Cash Classified Within Assets Held For Sale Period Increase Decrease 0.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20240331 Commitments And Contingencies USD 0 us-gaap/2024
0000927653-25-000036 20240331 Common Stock Dividends Per Share Declared 2.4000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Common Stock Par Or Stated Value Per Share 0.0100 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Common Stock Shares Issued 279000000.0000 shares 0 us-gaap/2024
0000927653-25-000036 20240331 Deferred Income Tax Liabilities Net 917000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Deferred Income Tax Liabilities Net 1029000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Finite Lived Intangible Assets Net 364000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Trademarks And Trade Names;
0000927653-25-000036 20250331 Finite Lived Intangible Assets Net 4000000.0000 USD 0 us-gaap/2024 Finite Lived Intangible Assets By Major Class= Other Intangible Assets;
0000927653-25-000036 20250331 Gain Loss Related To Litigation Settlement -108000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Goodwill 29000000.0000 USD 0 us-gaap/2024 Business Segments= Corporate;
0000927653-25-000036 20250331 Goodwill 2507000000.0000 USD 0 us-gaap/2024 Business Segments= Medical Surgical Solutions Segment;
0000927653-25-000036 20240331 Gross Profit 12828000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 3481000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Income Loss From Continuing Operations Per Basic Share 25.2500 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Income Loss From Continuing Operations Per Diluted Share 22.3900 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Income Loss From Discontinued Operations Net Of Tax 0.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share 0.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 3722000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20230331 Operating Expenses 7977000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Operating Income Loss 3909000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Operating Lease Expense 228000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Assets Noncurrent 3186000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20230331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax -63000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax 39000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax 24000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax 2000000.0000 USD 4 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax 30000000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest;
0000927653-25-000036 20250331 Other Comprehensive Income Loss Net Of Tax 59000000.0000 USD 4 us-gaap/2024 Equity Components= A O C I Accumulated Gain Loss Net Investment Hedges Including Noncontrolling Interest;
0000927653-25-000036 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 24000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Other Noncash Income Expense -424000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230630 Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long Term Debt 647000000.0000 USD 0 0000927653-25-000036 Debt Instrument= A380 Notes Due March152024; Longterm Debt Type= Loans Payable;
0000927653-25-000036 20250331 Payments For Repurchase Of Common Stock 3146000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Payments Of Dividends Common Stock 314000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Payments To Acquire Businesses Net Of Cash Acquired 24000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Payments To Acquire Software 168000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Payments To Acquire Software 322000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000927653-25-000036 20250331 Proceeds From Payments For Other Financing Activities -554000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Profit Loss 3722000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Provision For Doubtful Accounts 45000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Provision For Doubtful Accounts -130000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Repayments Of Short Term Debt 19964000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Restricted Cash Current 265000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20240331 Retained Earnings Accumulated Deficit 14978000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 327717000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20250331 Revenue From Contract With Customer Excluding Assessed Tax 11000000.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 2000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000927653-25-000036 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -17045000000.0000 USD 0 us-gaap/2024 Equity Components= Treasury Stock Common;
0000927653-25-000036 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -4000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest;
0000927653-25-000036 20230331 Stockholders Equity Other -1000000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000927653-25-000036 20230331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 4000000.0000 USD 4 0000927653-25-000036
0000927653-25-000036 20230331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures -160000000.0000 USD 4 0000927653-25-000036 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures -99000000.0000 USD 4 0000927653-25-000036 Equity Components= Treasury Stock Common;
0000927653-25-000036 20240331 Stock Repurchased During Period Value 3023000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Weighted Average Number Of Diluted Shares Outstanding 128100000.0000 shares 4 us-gaap/2024
0000927653-25-000036 20230331 Weighted Average Number Of Shares Outstanding Basic 141100000.0000 shares 4 us-gaap/2024
0000927653-25-000036 20240331 Increase Decrease In Receivables 2954000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20250331 Increase Decrease In Receivables 3935000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Inventory L I F O Reserve Period Charge -157000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Inventory L I F O Reserve Period Charge -157000000.0000 USD 4 us-gaap/2024 Business Segments= U S Pharmaceutical Segment; Consolidation Items= Operating Segments;
0000927653-25-000036 20250331 Litigation Reserve Noncurrent 5601000000.0000 USD 0 us-gaap/2024
0000927653-25-000036 20250331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 178000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20240331 Net Cash Provided By Used In Investing Activities -1072000000.0000 USD 4 us-gaap/2024
0000927653-25-000036 20230331 Net Income Loss 3560000000.0000 USD 4 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
Proceeds From Issuance Of Long Term Debt us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Long-Term Debt The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Cash Cash Equivalents Restricted Cash Classified Within Assets Held For Sale Period Increase Decrease 0000927653-25-000036 1 0 monetary D D Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease) Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.
Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 0 0 monetary D C Payments to Acquire Businesses, Net of Cash Acquired The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Long Term Debt And Capital Lease Obligations us-gaap/2024 0 0 monetary I C Long-Term Debt and Lease Obligation Amount of long-term debt and lease obligation, classified as noncurrent.
Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Net Income (Loss) Attributable to Noncontrolling Interest Amount of Net Income (Loss) attributable to noncontrolling interest.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Dividends Per Share Declared us-gaap/2024 0 0 perShare D Common Stock, Dividends, Per Share, Declared Aggregate dividends declared during the period for each share of common stock outstanding.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Increase Decrease In Receivables us-gaap/2024 0 0 monetary D C Increase (Decrease) in Receivables The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
Long Term Debt And Capital Lease Obligations Current us-gaap/2024 0 0 monetary I C Long-Term Debt and Lease Obligation, Current Amount of long-term debt and lease obligation, classified as current.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Payments To Acquire Software us-gaap/2024 0 0 monetary D C Payments to Acquire Software The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.
Receivables Net Current us-gaap/2024 0 0 monetary I D Receivables, Net, Current The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
Repayments Of Short Term Debt us-gaap/2024 0 0 monetary D C Repayments of Short-Term Debt The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
Restricted Cash Current us-gaap/2024 0 0 monetary I D Restricted Cash, Current Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Stockholders Equity Other us-gaap/2024 0 0 monetary D D Stockholders' Equity, Other This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Adjustments To Additional Paid In Capital Exercise Of Put Right 0000927653-25-000036 1 0 monetary D C Adjustments to Additional Paid in Capital, Exercise of Put Right Adjustments to Additional Paid in Capital, Exercise of Put Right
Derecognition Of Noncontrolling Interests 0000927653-25-000036 1 0 monetary D D Derecognition of Noncontrolling Interests Divestiture of Noncontrolling Interest
Formation Of Business 0000927653-25-000036 1 0 monetary D C Formation Of Business Formation Of Business
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Dividends Common Stock Cash us-gaap/2024 0 0 monetary D D Dividends, Common Stock, Cash Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Gross Profit us-gaap/2024 0 0 monetary D C Gross Profit Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
Increase Decrease In Accrued Taxes Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Taxes Payable The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Payments For Proceeds From Other Investing Activities us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Other Investing Activities Amount of cash (inflow) outflow from investing activities classified as other.
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options us-gaap/2024 0 0 monetary D D Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.
Restructuring Costs And Asset Impairment Charges us-gaap/2024 0 0 monetary D D Restructuring Costs and Asset Impairment Charges Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.
Income Loss From Continuing Operations Per Diluted Share us-gaap/2024 0 0 perShare D Income (Loss) from Continuing Operations, Per Diluted Share The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Income Loss From Discontinued Operations Net Of Tax us-gaap/2024 0 0 monetary D C Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Interest Expense Nonoperating us-gaap/2024 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Increase Decrease In Other Operating Capital Net us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Operating Assets and Liabilities, Net Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.
Operating Lease Expense us-gaap/2024 0 0 monetary D D Operating Lease, Expense Amount of operating lease expense. Excludes sublease income.
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Repayments Of Long Term Debt us-gaap/2024 0 0 monetary D C Repayments of Long-Term Debt The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 0000927653-25-000036 1 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest
Stock Issued During Period Shares Employee Stock Plans Net Of Forfeitures 0000927653-25-000036 1 0 shares D Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures
Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 0000927653-25-000036 1 0 monetary D C Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Income Taxes Paid Net us-gaap/2024 0 0 monetary D C Income Taxes Paid, Net Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders us-gaap/2024 0 0 monetary D D Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.
Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax Amount after tax and reclassification adjustments of other comprehensive income (loss).
Other Noncash Income Expense us-gaap/2024 0 0 monetary D C Other Noncash Income (Expense) Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Stock Repurchased During Period Value us-gaap/2024 0 0 monetary D D Stock Repurchased During Period, Value Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
Finite Lived Intangible Assets Net us-gaap/2024 0 0 monetary I D Finite-Lived Intangible Assets, Net Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Increase Decrease In Deferred Income Taxes us-gaap/2024 0 0 monetary D C Increase (Decrease) in Deferred Income Taxes The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.
Litigation Reserve Noncurrent us-gaap/2024 0 0 monetary I C Estimated Litigation Liability, Noncurrent Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Proceeds From Payments For Other Financing Activities us-gaap/2024 0 0 monetary D D Proceeds from (Payments for) Other Financing Activities Amount of cash inflow (outflow) from financing activities classified as other.
Stock Repurchased During Period Shares us-gaap/2024 0 0 shares D Stock Repurchased During Period, Shares Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
Increase Decrease In Operating Lease Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Income Loss From Continuing Operations Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Continuing Operations, Per Basic Share The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax us-gaap/2024 0 0 monetary D D Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Deferred Income Tax Liabilities Net us-gaap/2024 0 0 monetary I C Deferred Income Tax Liabilities, Net Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Gain Loss Related To Litigation Settlement us-gaap/2024 0 0 monetary D C Gain (Loss) from Litigation Settlement Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Asset Impairment Charges us-gaap/2024 0 0 monetary D D Other Asset Impairment Charges The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
Payments For Repurchase Of Common Stock us-gaap/2024 0 0 monetary D C Payments for Repurchase of Common Stock The cash outflow to reacquire common stock during the period.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Proceeds From Short Term Debt us-gaap/2024 0 0 monetary D D Proceeds from Short-Term Debt The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
Increase Decrease In Litigation Reserve 0000927653-25-000036 1 0 monetary D D Increase (Decrease) in Litigation Reserve Increase (Decrease) in Litigation Reserve
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.
Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long Term Debt 0000927653-25-000036 1 0 monetary D C Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Depreciation us-gaap/2024 0 0 monetary D D Depreciation The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Inventory L I F O Reserve Period Charge us-gaap/2024 0 0 monetary D D Inventory, LIFO Reserve, Period Charge The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Proceeds From Divestiture Of Businesses And Interests In Affiliates us-gaap/2024 0 0 monetary D D Proceeds from Divestiture of Businesses and Interests in Affiliates The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).
Treasury Stock Common Value us-gaap/2024 0 0 monetary I D Treasury Stock, Common, Value Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.
Adjustment For Amortization us-gaap/2024 0 0 monetary D D Amortization The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
Gain Loss On Sale Of Other Assets us-gaap/2024 0 0 monetary D C Gain (Loss) on Disposition of Other Assets Amount of gain (loss) on sale or disposal of other assets.
Minority Interest us-gaap/2024 0 0 monetary I C Equity, Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Payments Of Dividends Common Stock us-gaap/2024 0 0 monetary D C Payments of Ordinary Dividends, Common Stock Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Provision For Doubtful Accounts us-gaap/2024 0 0 monetary D D Accounts Receivable, Credit Loss Expense (Reversal) Amount of expense (reversal of expense) for expected credit loss on accounts receivable.
Treasury Stock Common Shares us-gaap/2024 0 0 shares I Treasury Stock, Common, Shares Number of previously issued common shares repurchased by the issuing entity and held in treasury.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0000927653-25-000036 9 27 CF 0 H Payments For Proceeds From Other Investing Activities us-gaap/2024 Other 1
0000927653-25-000036 3 1 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Revenues 0
0000927653-25-000036 3 2 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of sales 1
0000927653-25-000036 3 3 IS 0 H Gross Profit us-gaap/2024 Gross profit 0
0000927653-25-000036 3 4 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, distribution, general, and administrative expenses 1
0000927653-25-000036 3 5 IS 0 H Gain Loss Related To Litigation Settlement us-gaap/2024 Claims and litigation charges, net 0
0000927653-25-000036 3 6 IS 0 H Restructuring Costs And Asset Impairment Charges us-gaap/2024 Restructuring, impairment, and related charges, net 1
0000927653-25-000036 3 7 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 1
0000927653-25-000036 3 8 IS 0 H Operating Income Loss us-gaap/2024 Operating income 0
0000927653-25-000036 3 9 IS 0 H Nonoperating Income Expense us-gaap/2024 Other income, net 0
0000927653-25-000036 3 10 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest expense 1
0000927653-25-000036 3 11 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Income from continuing operations before income taxes 0
0000927653-25-000036 3 12 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax expense 1
0000927653-25-000036 3 13 IS 0 H Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Income from continuing operations 0
0000927653-25-000036 3 14 IS 0 H Income Loss From Discontinued Operations Net Of Tax us-gaap/2024 Loss from discontinued operations, net of tax 0
0000927653-25-000036 3 15 IS 0 H Profit Loss us-gaap/2024 Net income 0
0000927653-25-000036 3 16 IS 0 H Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 Net income attributable to noncontrolling interests 1
0000927653-25-000036 3 17 IS 0 H Net Income Loss us-gaap/2024 Net income attributable to McKesson Corporation 0
0000927653-25-000036 3 20 IS 0 H Income Loss From Continuing Operations Per Diluted Share us-gaap/2024 Continuing operations (in dollars per share) 0
0000927653-25-000036 3 21 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2024 Discontinued operations (in dollars per share) 0
0000927653-25-000036 3 22 IS 0 H Earnings Per Share Diluted us-gaap/2024 Total (in dollars per share) 0
0000927653-25-000036 3 24 IS 0 H Income Loss From Continuing Operations Per Basic Share us-gaap/2024 Continuing operations (in dollars per share) 0
0000927653-25-000036 3 25 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 Discontinued operations (in dollars per share) 0
0000927653-25-000036 3 26 IS 0 H Earnings Per Share Basic us-gaap/2024 Total (in dollars per share) 0
0000927653-25-000036 3 28 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Diluted (in shares) 0
0000927653-25-000036 3 29 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Basic (in shares) 0
0000927653-25-000036 4 1 CI 0 H Profit Loss us-gaap/2024 Net income 0
0000927653-25-000036 4 3 CI 0 H Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax us-gaap/2024 Foreign currency translation adjustments 0
0000927653-25-000036 4 4 CI 0 H Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax us-gaap/2024 Unrealized gains (losses) on cash flow and other hedges 0
0000927653-25-000036 4 5 CI 0 H Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax us-gaap/2024 Changes in retirement-related benefit plans 1
0000927653-25-000036 4 6 CI 0 H Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other comprehensive income (loss), net of tax 0
0000927653-25-000036 4 7 CI 0 H Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive income 0
0000927653-25-000036 4 8 CI 0 H Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive income attributable to noncontrolling interests 1
0000927653-25-000036 4 9 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive income attributable to McKesson Corporation 0
0000927653-25-000036 5 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000927653-25-000036 5 4 BS 0 H Receivables Net Current us-gaap/2024 Receivables, net 0
0000927653-25-000036 5 5 BS 0 H Inventory Net us-gaap/2024 Inventories, net 0
0000927653-25-000036 5 6 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other 0
0000927653-25-000036 5 7 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0000927653-25-000036 5 8 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, plant, and equipment, net 0
0000927653-25-000036 5 9 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating lease right-of-use assets 0
0000927653-25-000036 5 10 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0000927653-25-000036 5 11 BS 0 H Finite Lived Intangible Assets Net us-gaap/2024 Intangible assets, net 0
0000927653-25-000036 5 12 BS 0 H Other Assets Noncurrent us-gaap/2024 Other non-current assets 0
0000927653-25-000036 5 13 BS 0 H Assets us-gaap/2024 Total assets 0
0000927653-25-000036 5 16 BS 0 H Accounts Payable Current us-gaap/2024 Drafts and accounts payable 0
0000927653-25-000036 5 17 BS 0 H Long Term Debt And Capital Lease Obligations Current us-gaap/2024 Current portion of long-term debt 0
0000927653-25-000036 5 18 BS 0 H Operating Lease Liability Current us-gaap/2024 Current portion of operating lease liabilities 0
0000927653-25-000036 5 19 BS 0 H Accrued Liabilities Current us-gaap/2024 Other accrued liabilities 0
0000927653-25-000036 5 20 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0000927653-25-000036 5 21 BS 0 H Long Term Debt And Capital Lease Obligations us-gaap/2024 Long-term debt 0
0000927653-25-000036 5 22 BS 0 H Deferred Income Tax Liabilities Net us-gaap/2024 Long-term deferred tax liabilities 0
0000927653-25-000036 5 23 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Long-term operating lease liabilities 0
0000927653-25-000036 5 24 BS 0 H Litigation Reserve Noncurrent us-gaap/2024 Long-term litigation liabilities 0
0000927653-25-000036 5 25 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other non-current liabilities 0
0000927653-25-000036 5 26 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingent liabilities (Note 17) 0
0000927653-25-000036 5 28 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding 0
0000927653-25-000036 5 29 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.01 par value, 800 shares authorized, 279 and 278 shares issued at March 31, 2025 and 2024, respectively 0
0000927653-25-000036 5 30 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in capital 0
0000927653-25-000036 5 31 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained earnings 0
0000927653-25-000036 5 32 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0000927653-25-000036 5 33 BS 0 H Treasury Stock Common Value us-gaap/2024 Treasury shares, at cost, 154 and 148 shares at March 31, 2025 and 2024, respectively 1
0000927653-25-000036 5 34 BS 0 H Stockholders Equity us-gaap/2024 Total McKesson Corporation stockholders deficit 0
0000927653-25-000036 5 35 BS 0 H Minority Interest us-gaap/2024 Noncontrolling interests 0
0000927653-25-000036 5 36 BS 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Total deficit 0
0000927653-25-000036 5 37 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and deficit 0
0000927653-25-000036 6 6 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value (in dollars per share) 0
0000927653-25-000036 6 7 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized (in shares) 0
0000927653-25-000036 6 8 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued (in shares) 0
0000927653-25-000036 6 9 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding (in shares) 0
0000927653-25-000036 6 10 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value (in dollars per share) 0
0000927653-25-000036 6 11 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized (in shares) 0
0000927653-25-000036 6 12 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued (in shares) 0
0000927653-25-000036 6 13 BS 1 H Treasury Stock Common Shares us-gaap/2024 Treasury stock, shares (in shares) 0
0000927653-25-000036 7 12 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Beginning balance, common stock (in shares) 0
0000927653-25-000036 7 13 EQ 0 H Treasury Stock Common Shares us-gaap/2024 Beginning balance, treasury common stock (shares) 1
0000927653-25-000036 7 14 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Beginning balance 0
0000927653-25-000036 7 15 EQ 0 H Stock Issued During Period Shares Employee Stock Plans Net Of Forfeitures 0000927653-25-000036 Issuance of shares under employee plans, net of forfeitures (in shares) 0
0000927653-25-000036 7 16 EQ 0 H Stock Issued During Period Value Employee Stock Plans Net Of Forfeitures 0000927653-25-000036 Issuance of shares under employee plans, net of forfeitures 0
0000927653-25-000036 7 17 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Share-based compensation 0
0000927653-25-000036 7 18 EQ 0 H Stock Repurchased During Period Shares us-gaap/2024 Repurchase of common stock (in shares) 1
0000927653-25-000036 7 19 EQ 0 H Stock Repurchased During Period Value us-gaap/2024 Repurchase of common stock 1
0000927653-25-000036 7 20 EQ 0 H Net Income Loss Including Portion Attributableto Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 0000927653-25-000036 Net income 0
0000927653-25-000036 7 21 EQ 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive income (loss) 0
0000927653-25-000036 7 22 EQ 0 H Dividends Common Stock Cash us-gaap/2024 Cash dividends declared 1
0000927653-25-000036 7 23 EQ 0 H Minority Interest Decrease From Distributions To Noncontrolling Interest Holders us-gaap/2024 Payments to noncontrolling interests 1
0000927653-25-000036 7 24 EQ 0 H Adjustments To Additional Paid In Capital Exercise Of Put Right 0000927653-25-000036 Reclassification of recurring compensation to other accrued liabilities 0
0000927653-25-000036 7 25 EQ 0 H Formation Of Business 0000927653-25-000036 Formation of SCRI Oncology 0
0000927653-25-000036 7 26 EQ 0 H Derecognition Of Noncontrolling Interests 0000927653-25-000036 Derecognition of noncontrolling interests in McKesson Europe 1
0000927653-25-000036 7 27 EQ 0 H Stockholders Equity Other us-gaap/2024 Other 1
0000927653-25-000036 7 28 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Ending balance common stock (in shares) 0
0000927653-25-000036 7 29 EQ 0 H Treasury Stock Common Shares us-gaap/2024 Ending balance, treasury common stock (shares) 1
0000927653-25-000036 7 30 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Ending balance 0
0000927653-25-000036 8 1 EQ 1 H Common Stock Dividends Per Share Declared us-gaap/2024 Cash dividends declared per common share (in dollars per share) 0
0000927653-25-000036 9 2 CF 0 H Profit Loss us-gaap/2024 Net income 0
0000927653-25-000036 9 4 CF 0 H Depreciation us-gaap/2024 Depreciation 0
0000927653-25-000036 9 5 CF 0 H Adjustment For Amortization us-gaap/2024 Amortization 0
0000927653-25-000036 9 6 CF 0 H Other Asset Impairment Charges us-gaap/2024 Long-lived asset impairment charges 0
0000927653-25-000036 9 7 CF 0 H Increase Decrease In Deferred Income Taxes us-gaap/2024 Deferred taxes 1
0000927653-25-000036 9 8 CF 0 H Inventory L I F O Reserve Period Charge us-gaap/2024 Charges (credits) associated with last-in, first-out inventory method 0
0000927653-25-000036 9 9 CF 0 H Operating Lease Expense us-gaap/2024 Non-cash operating lease expense 0
0000927653-25-000036 9 10 CF 0 H Gain Loss On Sale Of Other Assets us-gaap/2024 Loss (gain) from sales of businesses and investments 1
0000927653-25-000036 9 11 CF 0 H Provision For Doubtful Accounts us-gaap/2024 Provision for bad debts 0
0000927653-25-000036 9 12 CF 0 H Other Noncash Income Expense us-gaap/2024 Other non-cash items 1
0000927653-25-000036 9 14 CF 0 H Increase Decrease In Receivables us-gaap/2024 Receivables 1
0000927653-25-000036 9 15 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventories 1
0000927653-25-000036 9 16 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Drafts and accounts payable 0
0000927653-25-000036 9 17 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Operating lease liabilities 0
0000927653-25-000036 9 18 CF 0 H Increase Decrease In Accrued Taxes Payable us-gaap/2024 Taxes 0
0000927653-25-000036 9 19 CF 0 H Increase Decrease In Litigation Reserve 0000927653-25-000036 Litigation liabilities 0
0000927653-25-000036 9 20 CF 0 H Increase Decrease In Other Operating Capital Net us-gaap/2024 Other 1
0000927653-25-000036 9 21 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash provided by operating activities 0
0000927653-25-000036 9 23 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Payments for property, plant, and equipment 1
0000927653-25-000036 9 24 CF 0 H Payments To Acquire Software us-gaap/2024 Capitalized software expenditures 1
0000927653-25-000036 9 25 CF 0 H Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 Acquisitions, net of cash, cash equivalents, and restricted cash acquired 1
0000927653-25-000036 9 26 CF 0 H Proceeds From Divestiture Of Businesses And Interests In Affiliates us-gaap/2024 Proceeds from sales of businesses and investments, net 0
0000927653-25-000036 9 28 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used in investing activities 0
0000927653-25-000036 9 30 CF 0 H Proceeds From Short Term Debt us-gaap/2024 Proceeds from short-term borrowings 0
0000927653-25-000036 9 31 CF 0 H Repayments Of Short Term Debt us-gaap/2024 Repayments of short-term borrowings 1
0000927653-25-000036 9 32 CF 0 H Proceeds From Issuance Of Long Term Debt us-gaap/2024 Proceeds from issuances of long-term debt 0
0000927653-25-000036 9 33 CF 0 H Repayments Of Long Term Debt us-gaap/2024 Repayments of long-term debt 1
0000927653-25-000036 9 34 CF 0 H Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long Term Debt 0000927653-25-000036 Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt 1
0000927653-25-000036 9 36 CF 0 H Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options us-gaap/2024 Issuances 0
0000927653-25-000036 9 37 CF 0 H Payments For Repurchase Of Common Stock us-gaap/2024 Share repurchases 1
0000927653-25-000036 9 38 CF 0 H Payments Of Dividends Common Stock us-gaap/2024 Dividends paid 1
0000927653-25-000036 9 39 CF 0 H Proceeds From Payments For Other Financing Activities us-gaap/2024 Other 0
0000927653-25-000036 9 40 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash used in financing activities 0
0000927653-25-000036 9 41 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of exchange rate changes on cash, cash equivalents, and restricted cash 0
0000927653-25-000036 9 42 CF 0 H Cash Cash Equivalents Restricted Cash Classified Within Assets Held For Sale Period Increase Decrease 0000927653-25-000036 Cash, cash equivalents, and restricted cash classified as Assets held for sale 0
0000927653-25-000036 9 43 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash, cash equivalents, and restricted cash 0
0000927653-25-000036 9 44 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents, and restricted cash at beginning of year 0
0000927653-25-000036 9 45 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents, and restricted cash at end of year 0
0000927653-25-000036 9 47 CF 0 H Restricted Cash Current us-gaap/2024 Less: Restricted cash at end of year included in Prepaid expenses and other 1
0000927653-25-000036 9 48 CF 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents at end of year 0
0000927653-25-000036 9 50 CF 0 H Interest Paid Net us-gaap/2024 Interest, net 0
0000927653-25-000036 9 51 CF 0 H Income Taxes Paid Net us-gaap/2024 Income taxes, net of refunds 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.